原发性胆汁性胆管炎治疗现状

doi:10.3969/j.issn.1672-5069.2021.03.038

Abstract

Abstract: Primary biliary cholangitis (PBC) is a chronic, progressive, non-suppurative inflammation of the small bile ducts in the liver. Ursodeoxycholic acid is the only first-line therapeutic drug at present. New progress has been made in the research on the efficacy of second-line drugs such as obieticholic acid, betts and immunosuppressants. The efficacy and safety of non-drug intervened measure are under investigation. There are also different treatment ways for different extrahepatic manifestations of patients with PBC. In this review, we put focus on the current progress of treatment for PBC patients.

Key words: Primary biliary cholangitis, Ursodeoxycholic acid, Obieticholic acid, Therapy

Zhang Xinhe, Tian Haoyu, Li Yiling. Current therapeutic strategy for patients with primary biliary cholangitis[J]. Journal of Practical Hepatology, 2021, 24(3): 453-456.

References

[1] Wasik U, Kempinska-Podhorodecka A, Bogdanos H, et al. Enhanced expression of miR-21 and miR-150 is a feature of anti-mitochondrial antibody-negative primary biliary cholangitis. Mol Med,2020,26(1):8.
[2]王立峰,李元元,金磊,等.原发性胆汁性肝硬化的流行病学与自然史变迁.临床肝胆病杂志,2015,31(2):165-170.
[3] Ye HL, Zhang JW, Chen XZ, et al. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci,2020,242:117175.
[4] Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.Gastroenterology,2013,144(3):560-569.
[5] Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Gut,2018,67(9):1568-1594.
[6] Fujita K, Nomura T, MorishitaA, et al. Prediction of transplant-free survival through albumin-bilirubin score in primary biliary cholangitis. J Clin Med,2019,8(8):1258.
[7] Huang C, Han W, Wang C, et al. Earlyprognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis: A Meta-analysis. Dis Mark,2019,2019:9121207.
[8] Yoo JJ, Cho EJ, Lee B, et al. Prognosticvalue of biochemical response modeis for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio. Gut Liver,2018,12(6):714-721.
[9] Liberopoulos EN, Florentin M, Elisaf MS, et al. Fenofibrate in primary biliary cirrhosis: A pilot study. Open Cardiovasc Med J,2010,4:120-6.
[10] Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxy cholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther,2016,43(2):283-293.
[11] Dohmen K, Mizuta T, Nakamuta M, et al. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol,2004,10(6):894-8.
[12] Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther,2011,33(2):235-242.
[13] Han XF, Wang QX, Liu Y, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy.J Dig Dis,2012,13(4):219-24.
[14] Grigorian AY, Mardini HE, Corpechot, et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.Clin Res Hepatol Gastroenterol,2015,39(3):296-306.
[15] Zhang Y, Li S, He L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.Drug Des Devel Ther,2015,9:2757-66.
[16] Klose G, Nitschmann S. Bezafibrate for primary biliary cholangitis: Bezafibrate in combination with ursodeoxycholic acid in primary biliary cholangitis (BEZURSO) trial.Internist (BERL),2018,59(12):1344-1346.
[17] Corpechot C, Chazouilleres O, Rousseau A, et al. Aplacebo-controlled trial of bezafibrate in primary biliary cholangitis.N Engl J Med,2018,378(23):2171-2181.
[18] Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.Drug Des Devel Ther,2015,9:5947.
[19] 奉白蕾,俞慧宏,沈薇.熊去氧胆酸联合苯扎贝特治疗难治性原发性胆汁性胆管炎的Meta分析.中国肝脏病杂志,2019,27(4):304-311.
[20] Dohmen K, Tanaka H, Haruno M. Effectiveness of fenofibrate in comparison to bezafibrate for patients withasymptomatic primary biliary cirrhosis.Fukuoka Igaku Zasshi,2013,104(10):350-361.
[21] Duan W, Ou X, Wang X, et al. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Rev Esp Enferm Dig,2018,110(9):557-563.
[22] Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.Drug Des Devel Ther,2015,9:5407-5419.
[23] Zhang H, Yang J, Zhu R, et al. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis.Drug Des Devel Ther,2015,9:567-574.
[24] Floreani A, Sun Y, Zou ZS, et al. Proposed therapies in primary biliary cholangitis.Expert Rev Gastroenterol Hepatol,2016,10(3):371-382.
[25] Leuschner M, Maler KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.Gastroenterology,1999,117(4):918-925.
[26] Angulo P, Jorgensen RA, Keach J, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.Hepatology,2000,31(2):318-323.
[27] Pagan B, Erdozain JC, Comas C, et al. Budesonide combined with ursodeoxycholic acid in primary biliary cirrhosis with advanced liver damage.Eur J Intern Med,2006,17(7):508-510.
[28] Hempfling W, Grunhage F, Diger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis.Hepatology,2003,38(1):196-202.
[29] Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial.Hepatology,2005,41(4):747-752.
[30] Rautiainen H, Farkkila M, Neuvonen M, et al. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis.Aliment Pharmacol Ther,2006,24(11-12):1545-1552.
[31] Floreani A, Mangini C. Primary biliary cholangitis: Old and novel therapy. Eur J Intern Med,2018,47:1-5.
[32] Levy C. Evolving role of obeticholic acid in primary biliary cholangitis. Hepatology,2018,67(5):1666-1668.
[33] Bowlus CL. Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepat Med,2016,8:89-95.
[34] Hischfield GM, Mason A, Luketic V, etal. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.Gastroenterology,2015,148(4):751-761.
[35] Nevens F, Andreone P, Mazzella G, et al. Aplacebo-controlled trial of obeticholic acid in primary biliary cholangitis.N Engl J Med,2016,375(7):631-43.
[36] Bowlus CL, Pockros PJ, Kremer AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis.Clin Gastroenterol Hepatol,2020,18(5):1170-1178.
[37] Ishigami F, Naka S, Takeshita K, et al. Bile salt tauroursodeoxycholic acid modulation of Bax translocation to mitochondria protects the liver from warm ischemia-reperfusion injury in the rat.Transplantation,2001,72(11):1803-7.
[38] Ma H, Zeng M, Han Y, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.Medicine (Baltimore),2016,95(47):e5391.
[39] Paridaens A, Raevens S, Devisscher L, et al. Modulation of the unfolded protein response by tauroursodeoxycholic acid counteracts apoptotic cell death and fibrosis in a mouse model for secondary biliary liver fibrosis. Int J Mol Sci,2017,18(1):214.
[40] 陈佳良,杨雪,张群,等.熊去氧胆酸联合中药治疗对原发性胆汁性胆管炎患者生物化学应答的影响:一项基于真实世界的队列研究.中华肝脏病杂志,2018,26(12):909-915.
[41] Huang YQ. Recent advances in the diagnosis and treatment of primary biliary cholangitis.World J Hepatol,2016,8(33):1419-1441.
[42] Sargin G, Senturk T, Cildag S. Rituximab therapy in rheumatoid arthritis and primary biliary cholangitis.Reumatol Clin,2019,15(6):e166-e167.
[43] Khanna A, Jopson L, Howel D, et al. Rituximabis ineffective for treatment of fatigue in primary biliary cholangitis: A phase 2 randomized controlled trial.Hepatology,2019,70(5):1646-1657.
[44] Arsenijevic A, Harrell CR, Fellabaum C, et al. Mesenchymal stem cells as new therapeutic agents for the treatment of primary biliary cholangitis. Anal Cell Pathol(Amst),2017,2017:7492836.
[45] Fan J, Tang X, Wang Q, et al. Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9.Stem Cell Res Ther,2018,9(1):237.
[46] Zhu Y, Wang Q, Tang X, et al. Mesenchymal stem cells enhance autophagy of human intrahepatic biliary epithelial cells in vitro.Cell Biochem Funct,2018,36(5):280-287.
[47] Lei J, Chai Y, Xiao J, et al. Antifibrotic potential of bone marrow-derived mesenchymal stem cells in biliary atresia mice.Mol Med Rep,2018,18(4):3983-3988.

Current therapeutic strategy for patients with primary biliary cholangitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yuan Pingge, Chen Wenwen. Insights to new medicine development for treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 305-307.
[2]	Xu Wenting, Zhang Jihong, Wei Dongjue, et al. Efficacy of tenofovir rescue therapy for patients with chronic hepatitis B and rtM204 mutation [J]. Journal of Practical Hepatology, 2021, 24(3): 335-338.
[3]	Wang Xue, Qu Falin, Qi Weili, et al. Balance of peripheral blood Treg cells/ Th17 cells in patients with chronic hepatitis B and its impact on response to telbivudine treatment [J]. Journal of Practical Hepatology, 2021, 24(3): 339-342.
[4]	Qi Mei, Zhang Ruijin, Tian Shuping, et al. Impacting factors in response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 371-374.
[5]	Wang Yunqiang, Wang Liping, Huang Dongmei, et al. Changes ofportal hemodynamics in patients with hepatitis B cirrhosis after transjugular intrahepatic portosystemic stent-shunt [J]. Journal of Practical Hepatology, 2021, 24(3): 399-402.
[6]	Wu Chang, Zhang Yuan’an, Peng Chunfen. Efficacy of endoscopic variceal ligation and carvedilol maintenance in the treatment of patients with liver cirrhosis and esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2021, 24(3): 403-406.
[7]	Zhao Kai, Xue Jinfeng, Xue Pengfei, et al. Application of Viatorr covered stent in TIPS for treatment of cirrhotics with portal hypertension [J]. Journal of Practical Hepatology, 2021, 24(3): 419-422.
[8]	Feng Hao, Lyu Haitao, Wang Ziwei, et al. Efficacy of one-step and step-by-steplaparoscopic cholecystectomy in the treatment of patients with gallbladder stones and common bile duct stones [J]. Journal of Practical Hepatology, 2021, 24(3): 435-438.
[9]	Guo Li, Song Yuanzong. Clinical management of pediatric patients with Alagille syndrome [J]. Journal of Practical Hepatology, 2021, 24(2): 160-163.
[10]	He Yufeng, Zhong Xiaoni, Huang Jianrong, et al. Short-term efficacy of tenofovir dipivoxil and entecavir in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(2): 200-203.
[11]	Nie Liu, Peng Hanming, Liao Dongliang. Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(2): 224-227.
[12]	Liu Yunhua, Da Rongfeng, Xu Hubo, et al. Therapeutic efficacy of polyene phosphatidylcholine in patients with anti-tuberculosis agents-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(2): 228-231.
[13]	Lin Cheng, Wang Tongbiao, Li Yueyong, et al. Short-term efficacy of magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in treatment of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(2): 232-235.
[14]	Zhang Yan, Xia Wenfang, Jin Jin, et al. Short-term observation ofglicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases and hepatogenic diabetes [J]. Journal of Practical Hepatology, 2021, 24(2): 240-243.
[15]	Li Man, Li Jing, Chen Wenling, et al. Clinical observation of external local high frequency thermotherapy and radiotherapy in the treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(2): 256-259.